Genmab Executes Share Buy-back Transactions in June 2025

The latest announcement is out from Genmab ( (GMAB) ).

On June 23, 2025, Genmab A/S announced the execution of transactions under its share buy-back program, initiated on March 25, 2025, to repurchase up to 2.2 million shares. The program, aimed at reducing capital and fulfilling commitments under the Restricted Stock Unit program, is expected to conclude by July 10, 2025. From June 16 to June 20, 2025, Genmab repurchased 500 shares, bringing the total accumulated shares under the program to 2,081,211. These transactions reflect Genmab’s strategic financial management and commitment to its shareholders.

The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s overall stock score is driven primarily by its strong financial performance, with a robust balance sheet and effective cash flow management. The technical analysis also supports a positive outlook, although the stock may be nearing overbought levels. Valuation metrics are favorable, though the lack of a dividend yield is a minor drawback.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics. Established in 1999, the company has a strong presence in North America, Europe, and Asia Pacific, and aims to transform the lives of people with cancer and other serious diseases through its proprietary pipeline, including bispecific T-cell engagers and antibody-drug conjugates.

Average Trading Volume: 1,447,879

Technical Sentiment Signal: Strong Sell

Current Market Cap: $13.05B

See more insights into GMAB stock on TipRanks’ Stock Analysis page.